Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Pfizer, COVID-19 and Health Canada
Pfizer v Moderna COVID vaccine patents battle to go to appeal in UK
Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday gave Pfizer permission to take the case to the Court of Appeal. Pfizer and its German partner BioNTech sued Moderna in London in September 2022,
Updated Pfizer-BioNTech’s COVID-19 vaccine approved by Health Canada
Health Canada approved Pfizer-BioNTech’s updated COVID-19 vaccine on Tuesday, marking its third authorization of vaccine formulations that protect against the most recently circulating variants of the virus.
Pfizer’s updated COVID-19 vaccine approved by Health Canada
The mRNA vaccine, called Comirnaty, targets the KP.2 subvariant of Omicron, replacing the previous version which targeted the XBB.1.5 Omicron subvariant.
Health Canada approves Pfizer's updated COVID-19 vaccine, manufacturer says
Pfizer Canada says Health Canada has approved its updated COVID-19 vaccine that protects against one of the most recently circulating variants of the virus.
Pfizer pulls sickle cell treatment Oxbryta
Pfizer’s Strategy Looks Shakier After Sickle-Cell Disappointment
The company said it was withdrawing Oxbryta, a daily pill for patients with the disease, a serious, lifelong condition.
Pfizer Sickle Cell Treatment Suspended by Europe in New Setback
European regulators suspended the approval of Pfizer Inc.’s sickle cell anemia drug, Oxbryta, citing a higher rate of disease complications in patients who started taking the drug.
Pfizer withdraws sickle cell disease treatment on risk of complication, death
U.S. drugmaker Pfizer said on Wednesday it was withdrawing its sickle cell disease treatment Oxbryta from all markets where it is approved, citing risks of a painful complication and deaths.
STAT
1d
Pharmalittle: We’re reading about Pfizer pulling a sickle cell pill, Moderna getting scolded, and more
Pfizer is removing its Oxbryta pill for sickle cell disease from all markets globally due to safety risks, including deaths.
fingerlakes1
20h
Judge tosses family’s lawsuit over son’s vaccine-related death
A federal judge has dismissed a lawsuit by a New York family who claimed the Department of Defense misled Americans into ...
2d
Pfizer Is Rising Past Covid-19
Pfizer Inc. ( PFE, Financial) rose to prominence during the Covid-19 pandemic for its rapid development of a vaccine and ...
1d
Judge dismisses family lawsuit against Dept. of Defense after 24-year-old’s “vaccine-related” death
A federal judge in Washington D.C. cited the government’s “general immunity” in dismissing a lawsuit that accused the ...
1d
on MSN
Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say
Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed ...
The Independent Singapore
2d
HSA approves Pfizer’s new RSV vaccine
This is the first RSV vaccine approved in Singapore for use in older adults and pregnant individuals, providing critical ...
CNET on MSN
6d
What to Know About Novavax, the 'Other' COVID Vaccine
Pfizer's and Moderna's formulas have been the go-to on pharmacy shelves, but Novavax remains an important option.
3d
Dr Roland denies instilling fear about Pfizer vaccine
SEPANG: Dr Roland Victor, who is charged with making and initiating the transmission of offensive videos about the Covid-19 ...
1d
on MSN
Slow progress on Pfizer's plan to sell drugs to low-income nations at not-for-profit price, says CEO
Pfizer has so far signed up less than a quarter of the countries targeted under a plan to make its medicines available to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
COVID
London
Moderna
Novavax
Oxbryta
Feedback